Global Immunoglobulin Market to Grow at a Slightly Higher Growth Rate on Demand Increase, Expects GBI Research

06 Jun 2013 • by Natalie Aster

The use of immunoglobulin as a treatment option for Alzheimer's disease is being investigated by all major companies, and the product pipeline is dominated by R&D in Phase II and III clinical trials. The recently completed Phase III study results of Baxter's Gammagard Liquid are anticipated in mid-2013. Similarly, Octapharma completed a Phase II study of its Octagam 10% IVIG for Alzheimer's disease and published positive results in January 2013. The approval of either of these products could change the immunoglobulin market landscape.

The global immunoglobulin market is expected to grow at a slightly higher growth rate in the forecast period due to continuing demand for immunoglobulin treatment for several indications, approval of existing Intravenous Immunoglobulin (IVIG) products for new indications, the expected approval of new Subcutaneous Immunoglobulins (SCIGs) and global blood product shortages.

New report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" by GBI Research provides an in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Report Details:

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease
Published: May, 2013
Pages: 91
Price: US$ 3,500.00

More information can be found in the report “Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease” by Timetric.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com